<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02713139</url>
  </required_header>
  <id_info>
    <org_study_id>ACH-CLP-03(05/12)</org_study_id>
    <nct_id>NCT02713139</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of the Association of Clotrimazole and Metronidazole in the Treatment of Vaginal Discharge From Different Etiologies.</brief_title>
  <acronym>Frauen</acronym>
  <official_title>Phase III, Multicenter, Randomized, Parallel, Open Label, Controlled and Comparative Study to Evaluate the Efficacy and Safety of the Association of Clotrimazole 200mg and Metronidazole 0,75% (Colpistatin 5DT®) Compared to Gynecological Flagyl®(Metronidazole 100mg/g) and the Vaginal Cream Gino-Canesten® 3 (Clotrimazole 20mg/g) in the Syndromic Treatment of the Vaginal Discharge From Different Etiologies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ache Laboratorios Farmaceuticos S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ache Laboratorios Farmaceuticos S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of the association
      clotrimazole 200mg and metronidazole 0,75%(Clopistatin 5DT®) and whether it is superior when
      compared with metronidazole 100mg/g (gynecologic Flagyl®) and clotrimazole 20mg/g
      (Gino-Canesten® 3) in the syndromic treatment of vaginal discharge from different etiologies.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Due to budget limitations, the company decided to withdraw this study.
  </why_stopped>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ceasing of the symptoms of vaginal discharge after 3(three) days of the end of the treatment</measure>
    <time_frame>From baseline to 3 days after the end of the treatment</time_frame>
    <description>Examination of the breasts and internal and external examination of the female genital organ.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Registry of Adverse Effects occurrence throughout the study</measure>
    <time_frame>From baseline to 30 days after the end of the treatment</time_frame>
    <description>Evaluation of Clinical and Physical examination and the measure of vital signs; Evaluation of Adverse effects; Evaluation of Laboratory exams; And evaluation of urine beta-hcg test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal microflora reconstitution through microbiological evaluation of vaginal material</measure>
    <time_frame>From baseline to 30 days after treatment's end</time_frame>
    <description>Evaluation of the collected vaginal material with the microbiological tests(Whiff, Gram, Affirm VPIII) and PCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatology recurrence and/or vaginal microflora alteration 30 days after the treatment's end</measure>
    <time_frame>From baseline to 30 days after treatment's end</time_frame>
    <description>Examination of the breasts and internal and external examination of the female genital organ.
Evaluation of the collected vaginal material with the microbiological tests(Whiff, Gram, Affirm VPIII) and PCR.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Sexual Active Women</condition>
  <condition>Vaginal Discharge</condition>
  <arm_group>
    <arm_group_label>Colpistatin 5DT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gynecological Flagyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gino-Canesten 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clotrimazole + Metronidazole</intervention_name>
    <description>Vaginal cream with Clotrimazole 200mg and Metronidazole 0,75%. Apply once per day, before bedtime, for 5 (five) days.</description>
    <arm_group_label>Colpistatin 5DT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Vaginal gel with Metronifdazole 100mg/g. Apply once per day, before bedtime, for 10(ten) days.</description>
    <arm_group_label>Gynecological Flagyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clotrimazole</intervention_name>
    <description>Vaginal cream with Clotrimazole 20mg/g. Apply once per day, before bedtime, for 3 (three) days.</description>
    <arm_group_label>Gino-Canesten 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects that have already started sexual activity;

          -  Subjects with complaints of vaginal discharge and had not received treatment in the 30
             days before the enrollment visit;

          -  Subjects in the premenopausal period must be under usage of acceptable contraceptive
             methods(oral contraceptive, injectable contraceptives, IUD, hormonal implant, hormone
             transdermal adhesive, tubal ligation) or are surgically sterile (bilateral
             oophorectomy or hysterectomy); or accept to utilize a barrier contraceptive provided
             by the sponsor during the period of the study;

          -  Subjects with the capacity to comprehend and understand her participation in this
             clinical trial, manifested through informed consent form, even if with the help of
             another person (Legal representative).

        Exclusion Criteria:

          -  Subjects with chronic diseases (diabetes mellitus, neoplasia, renal failure,
             tuberculosis) or any clinical and/or laboratory find (anamnesis, physical exam and/or
             laboratory tests) that is interpreted, in the investigator's opinion, as a risk to the
             subject's participation in the clinical trial;

          -  Menopausal women;

          -  Known hyper-sensibility to any of the products' components;

          -  Pregnant or lactating women;

          -  Subjects with active genital ulcer and/or with Genital herpes diagnosis;

          -  Diagnosis or suspicion of Inflammatory pelvic disease;

          -  Diagnosis of Vulvar condyloma acuminata;

          -  Subjects under the usage of systemic corticosteroids for a period superior than 2
             (two) months or under the usage of chemotherapeutics;

          -  Transplanted subjects;

          -  Subjects with history of active autoimmune diseases or with immune suppression;

          -  Subjects under the usage of medication or therapy described on the protocol item
             &quot;Prohibited Treatments&quot;;

          -  Subjects that have participated on a clinical trial in the last 12 months (Conselho
             Nacional de Saúde - Resolução 251, de 7 de agosto de 1997, item III, sub-item J),
             unless the subject can have a direct benefit, in the investigator opinion;

          -  Subject that have a kinship or bond with any employees of Sponsor or Research center;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo A. Junior, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scentryphar Pesquisa Clínica Ltda</affiliation>
  </overall_official>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2016</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaginal</keyword>
  <keyword>discharge</keyword>
  <keyword>women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginal Discharge</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

